Overview
AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that retains the lipolytic properties of GH without its anabolic or diabetogenic effects. It stimulates lipolysis through β3-adrenergic receptor pathways and inhibits lipogenesis. Phase 3 trials for obesity were conducted; it has since been investigated for osteoarthritis through cartilage repair properties.
Routes of Administration
Lipolysis research
Studied for obesity with some bioavailability
Research Profile
Mechanism of Action
Pharmacokinetics
Key Research Findings
Side Effects & Safety
Research Search Terms
Links open PubMed searches for peer-reviewed studies on this peptide.
Frequently Asked Questions
AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that retains the lipolytic properties of GH without its anabolic or diabetogenic effects. It stimulates lipolysis through β3-adrenergic receptor pathways and inhibits lipogenesis. Phase 3 trials for obesity were conducted; it has since been investigated for osteoarthritis through cartilage repair properties.
The reported half-life of AOD-9604 is ~30 minutes. Half-life refers to the time required for the plasma concentration to decrease by half through metabolic clearance.
In research settings, AOD-9604 is typically administered via: subcutaneous, oral. Route selection affects onset, bioavailability, and duration of action.
AOD-9604 is currently at the Phase III clinical trials — large-scale pivotal trials evaluating efficacy and safety. stage.
AOD-9604 profiles on Peptide United are for research and educational purposes only. This compound is not approved for human therapeutic use unless specifically noted. Always consult a qualified healthcare professional.
Linked Studies
2 studiesPubMed-indexed research associated with this peptide. Human trials ranked first.
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Dong Rak Kwon, Gi Young Park
To investigate the effects of AOD9604 intra-articular injections with or without hyaluronic acid (HA) in a collagenase-induced knee osteoarthritis (OA) rabbit model.
PubMed ↗The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
M Heffernan, R J Summers, A Thorburn +4 more
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (beta(3)-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression of beta(3)-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice. The importance of beta(3)-AR was verified when long-term treatment with hGH and AOD9604 in beta(3)-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in the beta(3)-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.
PubMed ↗Where to Source
Affiliate links — Peptide United may earn a commission on purchases. This does not affect our editorial independence.
Related Compounds